BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its
$20 million Greenhouse Fund. We invest in therapeutics, devices, diagnostics and platform technologies focused on human health.

BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies. Since our inception in 2002, BioAdvance has become one of the nation's leading investors providing pre-seed and seed-stage funding. To date we have committed more than $12 million to 22 seed-stage companies and 11 pre-seed companies and academic projects.  BioAdvance portfolio companies are working to develop products to treat health problems including Alzheimer's disease, obesity, diabetes, macular degeneration and cancer.